[go: up one dir, main page]

WO2002038174A3 - Vaccines containing recombinant hantavirus proteins, methods for producing said vaccines and their use - Google Patents

Vaccines containing recombinant hantavirus proteins, methods for producing said vaccines and their use Download PDF

Info

Publication number
WO2002038174A3
WO2002038174A3 PCT/DE2001/004213 DE0104213W WO0238174A3 WO 2002038174 A3 WO2002038174 A3 WO 2002038174A3 DE 0104213 W DE0104213 W DE 0104213W WO 0238174 A3 WO0238174 A3 WO 0238174A3
Authority
WO
WIPO (PCT)
Prior art keywords
vaccines
proteins
producing
methods
containing recombinant
Prior art date
Application number
PCT/DE2001/004213
Other languages
German (de)
French (fr)
Other versions
WO2002038174A2 (en
Inventor
Rainer Ulrich
Ausra Dargeviciute
Kestutis Sasnauskas
Aake Lundkvist
Original Assignee
Humboldt Uni Zu Berlin Univers
Inst Of Biotechnology
Rainer Ulrich
Ausra Dargeviciute
Kestutis Sasnauskas
Aake Lundkvist
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humboldt Uni Zu Berlin Univers, Inst Of Biotechnology, Rainer Ulrich, Ausra Dargeviciute, Kestutis Sasnauskas, Aake Lundkvist filed Critical Humboldt Uni Zu Berlin Univers
Priority to AU2002221553A priority Critical patent/AU2002221553A1/en
Publication of WO2002038174A2 publication Critical patent/WO2002038174A2/en
Publication of WO2002038174A3 publication Critical patent/WO2002038174A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12111—Hantavirus, e.g. Hantaan virus
    • C12N2760/12122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention relates to vaccines against hantaviruses, to methods for producing said vaccines and to their use. The scope of application is medicine or veterinary medicine. The invention is characterised by the use of a yeast high-expression system, which enables large quantities of recombinant hantavirus proteins to be obtained. The recombinant proteins are purified by density gradient centrifugation or affinity chromatography. Obtaining the proteins from yeast cells ensures that they are free of endotoxins and suitable for human applications as vaccines and in the development of diagnostics.
PCT/DE2001/004213 2000-11-08 2001-11-07 Vaccines containing recombinant hantavirus proteins, methods for producing said vaccines and their use WO2002038174A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002221553A AU2002221553A1 (en) 2000-11-08 2001-11-07 Vaccines containing recombinant hantavirus proteins, methods for producing said vaccines and their use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10055886.0 2000-11-08
DE10055886A DE10055886A1 (en) 2000-11-08 2000-11-08 Vaccines containing recombinant hantavirus proteins, processes for their preparation and their use

Publications (2)

Publication Number Publication Date
WO2002038174A2 WO2002038174A2 (en) 2002-05-16
WO2002038174A3 true WO2002038174A3 (en) 2003-08-28

Family

ID=7662912

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2001/004213 WO2002038174A2 (en) 2000-11-08 2001-11-07 Vaccines containing recombinant hantavirus proteins, methods for producing said vaccines and their use

Country Status (3)

Country Link
AU (1) AU2002221553A1 (en)
DE (1) DE10055886A1 (en)
WO (1) WO2002038174A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8333918B2 (en) 2003-10-27 2012-12-18 Kimberly-Clark Worldwide, Inc. Method for the production of nonwoven web materials
CN101249261B (en) * 2008-03-18 2010-10-27 中国疾病预防控制中心病毒病预防控制所 A kind of hemorrhagic fever with renal syndrome mucosal immunity vaccine and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995000648A1 (en) * 1993-06-24 1995-01-05 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Nucleic acids of a novel hantavirus and reagents for detection and prevention of infection
WO1999001153A1 (en) * 1997-07-03 1999-01-14 The University Of New Mexico Rio mamore hantavirus
DE19750220A1 (en) * 1997-11-13 1999-05-20 Max Delbrueck Centrum Producing polyoma virus-like particles in yeast for gene therapy, vaccine development and diagnosis
WO2000044406A2 (en) * 1999-01-29 2000-08-03 U.S. Medical Research Institute Of Infectious Diseases Dna vaccines against hantavirus infections

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916754A (en) * 1995-02-17 1999-06-29 The United States Of America As Represented By The Department Of Health And Human Services Bayou hantavirus and related methods
US5879968A (en) * 1996-11-18 1999-03-09 International Rectifier Corporation Process for manufacture of a P-channel MOS gated device with base implant through the contact window

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995000648A1 (en) * 1993-06-24 1995-01-05 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Nucleic acids of a novel hantavirus and reagents for detection and prevention of infection
WO1999001153A1 (en) * 1997-07-03 1999-01-14 The University Of New Mexico Rio mamore hantavirus
DE19750220A1 (en) * 1997-11-13 1999-05-20 Max Delbrueck Centrum Producing polyoma virus-like particles in yeast for gene therapy, vaccine development and diagnosis
WO2000044406A2 (en) * 1999-01-29 2000-08-03 U.S. Medical Research Institute Of Infectious Diseases Dna vaccines against hantavirus infections

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DARGEVICIUTE A ET AL: "Yeast-expressed Puumala hantavirus nucleocapsid protein induces protection in a bank vole model", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 20, no. 29-30, 4 October 2002 (2002-10-04), pages 3523 - 3531, XP004381816, ISSN: 0264-410X *

Also Published As

Publication number Publication date
DE10055886A1 (en) 2002-05-29
WO2002038174A2 (en) 2002-05-16
AU2002221553A1 (en) 2002-05-21

Similar Documents

Publication Publication Date Title
WO2002020569A3 (en) Mammalian genes; related reagents and methods
CA2113712A1 (en) Papilloma virus vaccine
DE3750342D1 (en) Human gamma interferon-specific receptor protein, antibodies against this protein, methods for producing this protein and antibody and compositions containing this protein and antibody.
DE60336228D1 (en) PROCESS FOR THE SIMULTANEOUS PREPARATION OF MULTIPLE PROTEINS; VECTORS AND CELLS THAT APPLY TO THEM
ATE405650T1 (en) PRODUCTION OF WHOLE ANTIBODIES IN PROKARYONTIC CELLS
WO2000039299A3 (en) Streptococcus antigens
NZ524888A (en) Nucleic acids and proteins from streptococcus groups A & B
WO1999031236A3 (en) EXTENDED cDNAs FOR SECRETED PROTEINS
EP1127170A4 (en) HUMAN MONOCLONAL ANTIBODIES TO HUMAN PAN-HEPATITIS C VIRUS
DK0942983T3 (en) Streptococcus pneumoniae antigens and vaccines
WO1999025825A3 (en) EXTENDED cDNAs FOR SECRETED PROTEINS
WO2004078098A3 (en) Peptides associated with hla-dr mhc class ii molecules involved in autoimmune diseases
EA200801509A1 (en) HUMAN MONOCLONAL ANTIBODIES TO PROTEINTHYROSINKINASE 7 (PTK7) AND METHODS OF APPLICATION OF ANTIBODIES AGAINST PTK7
WO2008060367A3 (en) Human antibodies that bind cxcr4 and uses thereof
PT1062325E (en) PURIFICATION OF VIRUS PREPARATIONS
EP0554389A4 (en) Molecular clones of hiv-1 and uses thereof
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
WO1998011226A3 (en) Mammalian chemokines, related reagents
WO1998023750A3 (en) Mammalian chemokines
WO2002038174A3 (en) Vaccines containing recombinant hantavirus proteins, methods for producing said vaccines and their use
ATE336504T1 (en) PURIFICATION PROCESS FOR PRODUCING MANNAN BINDING LECTIN (MBL) AND MEDICAL PREPARATION CONTAINING MBL
DE60025016D1 (en) A fusion protein of HPV L1 and a peptide which can form a VLP and which can serve as a vehicle for introducing a peptide into a cell, as well as its medical uses
AP2368A (en) Novel expression vectors and uses thereof.
ATE311456T1 (en) NUCLEIC ACID MOLECULES ENCODING PROTEINS THAT MEDIATE THE ADHESION OF NEISSERIA CELLS TO HUMAN CELLS
WO2002059345A3 (en) Nucleic acid encoding ion transporter component protein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WD Withdrawal of designations after international publication

Free format text: DE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP